Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA.
Bone Marrow Transplant. 2013 Jan;48(1):63-7. doi: 10.1038/bmt.2012.95. Epub 2012 Jun 18.
Hematological malignancy patients not referred by their primary hematologist/medical oncologist suffer disparate access to allogeneic hematopoietic cell transplantation (HCT). However, investigation into physician, system and patient factors relevant to this decision making is lacking. We surveyed a national randomized sample of practicing hematologists/medical oncologists identified through the AMA (American Medical Association) masterfile. A modified Dillman approach was utilized to encourage survey response. From 1200 surveyed, a total of 113 physicians responded. In all, 68% were male, 62% identified as White/non-Hispanic, 79% practiced in non-academic settings and 80% reported spending 75-100% of their professional effort in clinical care. Using clinical vignettes, we detected significantly increased odds for HCT non-referral according to age (age 60 vs 30, odds ratio (OR) 8.3, 95% confidence interval (CI): 5.9-11.7, P<0.0001), insurance coverage (no coverage vs coverage, OR 6.9, 95% CI: 5.2-9.1, P<0.0001) and race (African-American vs Caucasian, OR 2.4, 95% CI: 1.9-2.9, P<0.0001). Physician (perception of HCT risks), system (insurance coverage) and patient (age, social support and co-morbid illness) factors were strongly endorsed by respondents as important determinants of their HCT referral practices. These data speak to important factors relevant to HCT referral practices, and highlight several opportunities for education and intervention to reduce current disparities.
血液系统恶性肿瘤患者如果未经过其初级血液科医生/肿瘤内科医生转诊,将无法获得异体造血细胞移植(HCT)。然而,目前对于影响这一决策的医生、系统和患者因素的研究还很缺乏。我们调查了通过美国医学协会(AMA)主文件确定的全国范围内的随机抽取的执业血液科医生/肿瘤内科医生。采用改良的迪尔曼方法来鼓励调查回应。在调查的 1200 名医生中,共有 113 名医生做出了回应。所有受访者中,68%为男性,62%为白种人/非西班牙裔,79%在非学术环境中执业,80%的人报告将 75-100%的专业精力投入到临床护理中。通过临床案例,我们发现根据年龄(60 岁与 30 岁相比)、保险覆盖范围(无覆盖与有覆盖相比)和种族(非裔美国人与白人相比),HCT 转诊的可能性显著增加(年龄 60 岁与 30 岁相比,比值比(OR)为 8.3,95%置信区间(CI)为 5.9-11.7,P<0.0001),(无覆盖与有覆盖相比,OR 为 6.9,95% CI 为 5.2-9.1,P<0.0001)和(非裔美国人与白人相比,OR 为 2.4,95% CI 为 1.9-2.9,P<0.0001)。医生(对 HCT 风险的看法)、系统(保险覆盖范围)和患者(年龄、社会支持和合并疾病)因素被受访者强烈认为是其 HCT 转诊实践的重要决定因素。这些数据说明了与 HCT 转诊实践相关的重要因素,并强调了一些教育和干预的机会,以减少当前的差异。